background preloader

TUBERCULOSE ET ANTIBIORESISTANCE

Facebook Twitter

EUROSURVEILLANCE 12/01/17 A joint cross-border investigation of a cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany in 2014 using classic, genotyping and whole genome sequencing methods: lessons learnt. Int J Tuberc Lung Dis. 2016 Apr;20(4):448-55. Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. CLINICAL MICROBIOLOGY AND INFECTION 10/12/16 Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin resistance-conferring mutation undetected by commercial assays.

Am J Trop Med Hyg 2016 16-0120 Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis. + Author Affiliations + Author Notes Financial support: This study was funded by the Belgian Directorate-General for Development Cooperation (DGDC) through an institutional collaboration between the Institute of Tropical Medicine in Antwerp, Belgium, and the Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru.

Am J Trop Med Hyg 2016 16-0120 Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis

Authors' addresses: Jimena Collantes, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mail: jimena_collantes@hotmail.com. PARLEMENT EUROPEEN - Réponse à question E-007826-15 Drug-resistant TB and immigration. IDW 02/02/16 Extrem resistenter Tuberkulose-Erreger entwickelt weitere Resistenzen gegen neue Antibiotika. Extrem resistenter Tuberkulose-Erreger entwickelt weitere Resistenzen gegen neue Antibiotika Ergänzung vom 02.02.2016 Wissenschaftlerinnen und Wissenschaftlern unter Leitung des Leibniz Forschungszentrums Borstel, des Instituts für Mikrobiologie und Laboratoriumsdiagnostik in Gauting, des Instituts für Medizinische Mikrobiologie der Universität Zürich und des Deutschen Zentrums für Infektionsforschung (DZIF) haben bei einem Tuberkulose-Patienten zum erstem Mal einen extrem resistenten Mycobacterium tuberculosis Stamm mit zusätzlichen Resistenzen gegenüber den neuen Antibiotika Delamanid und Bedaquilin nachgewiesen.

IDW 02/02/16 Extrem resistenter Tuberkulose-Erreger entwickelt weitere Resistenzen gegen neue Antibiotika

Mit über neun Millionen Fällen und mehr als eineinhalb Millionen Toten pro Jahr ist die Tuberkulose (TB) immer noch eine der gefährlichsten Infektionskrankheiten weltweit. CDC EID – NOV 2015 – Au sommaire notamment: Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia ; Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.V.

CDC EID – NOV 2015 – Au sommaire notamment: Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia ;

Ershova, D.A. Kaminski, J.P. Cegielski, E.V. Kurbatova); Vladimir Oblast TB Dispensary, Vladimir, Russia (G.V. Volchenkov, T.R. Suggested citation for this article Abstract. INTECH - FEV 2012 - Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance. Edited by Pere-Joan Cardona, ISBN 978-953-307-948-6, 376 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 licenseDOI: 10.5772/2477 In 1957, a Streptomyces strain, the ME/83 (S.mediterranei), was isolated in the Lepetit Research Laboratories from a soil sample collected at a pine arboretum near Saint Raphael, France.

INTECH - FEV 2012 - Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance

This drug was the base for the chemotherapy with Streptomicine. The euphoria generated by the success of this regimen lead to the idea that TB eradication would be possible by the year 2000. Thus, any further drug development against TB was stopped. EUROSURVEILLANCE 17/10/13 Au sommaire:Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 20. Multidrug-resistant tuberculosis (MDR-TB; resistance to at least rifampicin and isoniazid) is a global public health concern.

EUROSURVEILLANCE 17/10/13 Au sommaire:Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 20

In 2010–2011, Uzbekistan, in central Asia, conducted its first countrywide survey to determine the prevalence of MDR-TB among TB patients. The proportion of MDR-TB among new and previously treated TB patients throughout the country was measured and risk factors for MDR-TB explored. A total of 1,037 patients were included. MDR-TB was detected in 165 treatment-naïve (23.2%; 95% confidence interval (CI) 17.8%–29.5%) and 207 previously treated (62.0%; 95% CI: 52.5%–70.7%) patients.

Références francophones

Documents OMS. Documents CDC. The worldwide epidemic of multidrug-resistant tuberculosis : The Lancet Infectious Diseases. WHO estimates that a third of the world's population is infected with Mycobacterium tuberculosis.

The worldwide epidemic of multidrug-resistant tuberculosis : The Lancet Infectious Diseases

In 2009, there were almost 9 million new cases of tuberculosis and the disease killed almost 1 million people around the world. Since the discovery of the BCG vaccine, and the development of new antibiotics in the 1950s, the incidence of tuberculosis has fallen substantially. From 1995 to 2009, about 49 million people received treatment for the disease, 41 million of whom were cured, saving up to 6 million.

However, multidrug-resistant (MDR) tuberculosis—ie, resistance to two of the most potent drugs, rifampicin and isoniazid—threatens to turn the tide against the medical advances of the past century. In 2008, WHO estimated that there were 440 000 cases of MDR tuberculosis around the world; but because culture and PCR methods for diagnosis are unreliable for resistant disease, WHO estimates that only 11% of actual cases were detected in 2009. PLOS 16/06/11 Dynamics of Antibiotic Resistant Mycobacterium tuberculosis during Long-Term Infection and Antibiotic Treatment.

For an infecting bacterium the human body provides several potential ecological niches with both internally (e.g. host immunity) and externally (e.g. antibiotic use) imposed growth restrictions that are expected to drive adaptive evolution in the bacterium, including the development of antibiotic resistance.

PLOS 16/06/11 Dynamics of Antibiotic Resistant Mycobacterium tuberculosis during Long-Term Infection and Antibiotic Treatment

To determine the extent and pattern of heterogeneity generated in a bacterial population during long-term antibiotic treatment, we examined in a monoclonal Mycobacterium tuberculosis infection antibiotic resistant mutants isolated from one patient during a 9-years period. There was a progressive accumulation of resistance mutations in the infecting clone. Furthermore, apparent clonal sweeps as well as co-existence of different resistant mutants were observed during this time, demonstrating that during treatment there is a high degree of dynamics in the bacterial population. Figures Editor: Sebastien Gagneux, Swiss Tropical and Public Health Institute, Switzerland Introduction.

Tuberculose humaine. Extensively drug-resistant tuberculosis. Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs.

Extensively drug-resistant tuberculosis

XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB). XDR-TB raises concerns of a future TB epidemic with restricted treatment options, and jeopardizes the major gains made in TB control and progress on reducing TB deaths among people living with HIV/AIDS. It is therefore vital that TB control be managed properly and new tools developed to prevent, treat and diagnose the disease. The true scale of XDR-TB is unknown as many countries lack the necessary equipment and capacity to accurately diagnose it. It is estimated however that there are around 40,000 cases per year. THE ROYAL SOCIETY - 2001 - Will tuberculosis become resistant to all antibiotics? SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL - 2008 - Thèse en ligne:Molecular characterisation of antibioticresistance in M. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis. Schweiz Med Wochenschr 2000;130:1909–13 Drug-resistant tuberculosis: resistance mechanisms and rapid susceptibility testing.

Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. The global increase in tuberculosis which has occurred in the 1980s and 1990s, and the associated re-emergence of resistance to antituberculous drugs, has focused attention on recent trends in resistance in Europe and the United States.1–3 In the United Kingdom overall drug resistance levels have been low.4 A surveillance system, the UK Mycobacterial Resistance Network (MYCOBNET), was established in 1994 by the Public Health Laboratory Service to record drug resistance in laboratory isolates of tuberculosis.

We used data from this network to examine resistance among people with newly diagnosed tuberculosis. Subjects, methods, and results We analysed the data on initial isolates of Mycobacterium tuberculosis complex referred to United Kingdom reference laboratories5 during 1994 to 1996. Initial isolates were defined as the first positive culture from a person from whom no positive culture had been recorded during the past 12 months. Comment. INSTITUTE OF MEDICINE - APRIL 2011 - The New Profile of Drug-Resistant Tuberculosis in Russia - Summary of a Workshop. Pharmaceuticals 2010, 3, 2268-2290 Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial.